Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
The group’s point-of-care Car-T push looks to have stalled.
After earlier masked probody setbacks, CytomX surprises with CX-2051.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Minghui’s MHB088C will soon start phase 3 in China.
Imfinzi hits on disease-free survival, but BCG won't be displaced.
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
